Represents the amount of potential payments that could be received under the collaborative agreement.

No definition available.

Name:	imgn_CollaborativeArrangementMilestonePaymentsPotential
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include milestone and licensing fees revenue. Milestone revenue is consideration received upon achieving contractual goals. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets.

+ References

No definition available.

+ Details

Name:	imgn_LicenseAndMilestoneFees
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the number of licenses terminated.

+ References

No definition available.

+ Details

Name:	imgn_NumberOfLicensesTerminated
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of single-target licenses the company has right to use.

+ References

No definition available.

+ Details

Name:	imgn_NumberOfSingleTargetLicenses
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of fee received for each license under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	imgn_ProceedsFromCollaboratorsPerLicense
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cumulative earnings (deficits) for relevant time periods.

+ References

No definition available.

+ Details

Name:	us-gaap_CumulativeEarningsDeficit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=imgn_AmgenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_RegulatoryMilestoneInvestigationalNewDrugApplicationFilingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_PhaseIIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Agreements - Amgen (Details)	1 Months Ended					3 Months Ended														6 Months Ended		12 Months Ended
Agreements - Amgen (Details)	Feb. 29, 2016 item	Dec. 31, 2015 item	Sep. 30, 2015 USD ($)	Oct. 31, 2013 USD ($)	May 31, 2013 USD ($) item	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($) item	Dec. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2000 USD ($) item
Collaborative Agreements disclosures
License and milestone fees						$ 29,580,000	$ 79,000	$ 31,080,000	$ 18,730,000	$ 5,076,000	$ 76,000	$ 76,000	$ 10,077,000	$ 10,692,000	$ 6,070,000	$ 5,086,000	$ 5,078,000	$ 41,417,000	$ 6,234,000	$ 5,152,000	$ 16,762,000	$ 79,469,000	$ 15,305,000	$ 26,915,000	$ 57,815,000
Remaining arrangement consideration to be recognized as license revenue						6,800,000				7,100,000										7,100,000		6,800,000	7,100,000
Costs related to the research and development services						39,843,000	$ 31,689,000	$ 35,319,000	$ 32,888,000	$ 33,657,000	$ 32,909,000	$ 38,652,000	$ 36,094,000	$ 38,199,000	$ 35,132,000	$ 30,437,000	$ 25,666,000	$ 27,647,000	$ 28,018,000	$ 66,566,000	$ 73,331,000	$ 139,739,000	$ 141,312,000	148,077,000	111,768,000
Amgen
Collaborative Agreements disclosures
Number of single-target licenses \| item		4			1																	2				3
Fee received per license				$ 500,000	$ 500,000																					$ 1,000,000
Number of licenses terminated \| item	2
Potential milestone payments				34,000,000
Cumulative earnings						3,000,000																$ 3,000,000
Costs related to the research and development services																						0		$ 15,000	$ 62,000
Amgen \| Development milestones
Collaborative Agreements disclosures
Potential milestone payments				9,000,000
Amgen \| IND application filed
Collaborative Agreements disclosures
Potential milestone payments						1,000,000																1,000,000
License and milestone fees			$ 1,000,000
Amgen \| Phase 2 clinical trial
Collaborative Agreements disclosures
Potential milestone payments						$ 3,000,000																$ 3,000,000
Amgen \| Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payments				20,000,000
Amgen \| Sales milestones
Collaborative Agreements disclosures
Potential milestone payments				$ 5,000,000